Human immunodeficiency virus and the liver: Lessons learned and still to be learned

Seminars in Liver Disease

Volumn 23, Issue 2, 2003, Pages 107-114

  Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ERYTHROPOIETIN; FIALURIDINE; INTERFERON; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EDITORIAL; FATIGUE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; SUPERINFECTION; VOMITING;

HEPATITIS A; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 0037945498     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39944     Document Type: Editorial

References (32)

1. Larrat S, Stanke-Labesque F, Plage A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003;47:124-129
2. Vogt MW. Interaction between didanosine and ribavirin. Science 1987;235:1376-1379
3. Mauss S. Risk factors for hepatic decompensation in cirrhotic patients with HIV-HCV coinfection treated with peg-interferon alfa or interferon alfa and ribavirin or placebo. Presented at the European Congress on AIDS. November 3, 2002; Glasgow, Scotland
4. Esteban R. Treatment of chronic hepatitis in HCV/HIV coinfected patients. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain. MoOrB113
5. Dieterich DT. Epoetin alfa treatment of anemic HCV patients allows for maintenance of ribavirin dose, increases hemoglobin levels and improves quality of life. Am J Gastroenterol 2003; (in press)
6. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185:S128-S137
7. Nelson M, Portsmouth S, Stebbing J, et al. An open label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals AIDS 2003;17:F7-F10
8. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306
9. Stapleton JT. GB virus type C/hepatitis G virus. Semin Liver Dis 2003;23:137-148
10. Roland ME, Carlson L, Ragni M, et al. Solid organ transplantation in HIV-infected recipients: forty-seven cases in the HAART era. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain. Abstract MoOr B1060
11. Pallella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 1998;338:853-860
12. Kaplowitz N, Lewis JH, Watkins PB. Did this drug cause my patient's hepatitis? Ann Intern Med 2002;136:480-483
13. Montessori V, Harris J, Montaner JSG. Nucleoside analogue liver toxicity. Semin Liver Dis 2003;23:167-172
14. Lewis W, Dalakis MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-421
15. Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acid and their response to treatment manipulation in HIV infected individuals - a case series Clin Infect Dis 2001;33:2072-2074
16. Sulkowski MS. Protease inhibitor toxicity. Semin Liver Dis 2003;23:183-194
17. Carr A, Samaraas K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58
18. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70
19. Sutinen J, Hakkinen A, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy AIDS 2002;16:2183-2193
20. Brunt EM. NASH: definition and pathology. Semin Liver Dis 2001;21:3-16
21. Gelato MC. Improved insulin sensitivity with body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31:163-170
22. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-179
23. Schambelan M, Benson C, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an IAS-USA Panel. J Acquit Immune Defic Syndr 2002;31:257-275
24. Cheeseman SH, Havlir D, McLauglin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:141-145
25. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, ziodovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-1030
26. Riesler R, Servoss J, Sherman K, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials ACTG Liver Disease Focus Group. Presented at the IAS 2001. July 8, 2001; Buenos Aires, Argentina. Abstract 43
27. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rept 2001;49:1153-1156
28. Van der Horst C, et al. FTC 302 results of a randomized trial. Presented at the Conference on Retroviruses and Opportunistic Infections. February 3, 2001; Chicago, IL. Abstract 18
29. Stern JO, et al. Nevirapine hepatic safety project. Presented at the XIV International AIDS Conference. July 8, 2002; Barcelona, Spain
30. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002 updated recommendations of the IAS-USA panel. JAMA 2002;288:222-235
31. van Leth, F, Hassink E, Phanphk P, et al. Results of the 2NN study: a randomized comparative trial of first line antitretiviral therapy with regimens containing either nevirapine alone, efavirenz alone, or both drugs combined together with stavudine and lamivudine. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. February 14, 2003; Boston. Abstract 176
32. Evans WE, McLeod HL. Pharmacogenomics drug disposition, drug targets and side effects. N Engl J Med 2003;348: 538-549